• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Assembly Biosciences Inc.

    4/17/24 4:15:05 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASMB alert in real time by email
    DEFA14A 1 asmb-defa14a-2024_notice.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934 (Amendment No. )

     

    ☒ Filed by the Registrant

     

    ☐ Filed by a party other than the Registrant

     

     

    CHECK THE APPROPRIATE BOX:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under to § 240.14a‑12

    img80631878_0.jpg 

    Assembly Biosciences, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

     

    PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY):

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6 and 0-11

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

     

    img80631878_1.jpg 

     

    Your Vote Counts! ASSEMBLY BIOSCIENCES, INC. 2024 Annual Meeting Vote by May 28, 2024 11:59 PM ET assemblybio ASSEMBLY BIOSCIENCES, INC. TWO TOWER PLACE, 7TH FLOOR SOUTH SAN FRANCISCO, CA 94080 V43463-P10418 You invested in ASSEMBLY BIOSCIENCES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 29, 2024. Get informed before you vote View the Notice of Assembly Biosciences, Inc.’s 2024 Annual Meeting of Stockholders and Proxy Statement and Annual Report for the fiscal year ended December 31, 2023 online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 15, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 29, 2024 8:00 A.M. PDT Virtually at: www.virtualshareholdermeeting.com/ASMB2024 *Please check the meeting materials for any special requirements for meeting attendance.

     

     


     

     

    img80631878_2.jpg 

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. Election of Directors Nominees: 1a. William R. Ringo, Jr. For 1b. Anthony E. Altig For 1c. Tomas Cihlar, Ph.D. For 1d. Gina Consylman For 1e. Robert D. Cook II For 1f. Sir Michael Houghton, Ph.D. For 1g. Lisa R. Johnson-Pratt, M.D. For 1h. Susan Mahony, Ph.D. For 1i. John G. McHutchison, A.O., M.D. For 1j. Jason A. Okazaki For 2. Approval, on a non-binding advisory basis, of our named executive officers’ compensation. For 3. Vote, on a non-binding advisory basis, on the frequency of future advisory votes to approve our named executive officers’ compensation. 1 Year 4. Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. For 5. Approval of an amendment and restatement to our 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 220,000 shares. For 6. Approval of an amendment and restatement of our 2018 Employee Stock Purchase Plan to increase the authorized number of shares reserved for issuance to 164,500 shares and remove the maximum number of shares purchasable under the plan per offering period. For NOTE: Your proxy holder will also vote in their discretion upon such other matters that may properly come before the meeting and any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V43464-P10418

     

     


    Get the next $ASMB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASMB

    DatePrice TargetRatingAnalyst
    9/24/2025$38.00Mkt Outperform
    Citizens JMP
    8/18/2025$50.00Buy
    H.C. Wainwright
    3/25/2025$31.00Buy
    Guggenheim
    9/20/2024$2.00 → $35.00Hold → Buy
    Jefferies
    9/13/2021$3.50Neutral
    HC Wainwright & Co.
    9/2/2021Outperform → Market Perform
    William Blair
    More analyst ratings

    $ASMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens JMP initiated coverage on Assembly Biosciences with a new price target

    Citizens JMP initiated coverage of Assembly Biosciences with a rating of Mkt Outperform and set a new price target of $38.00

    9/24/25 7:55:39 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Assembly Biosciences with a new price target

    H.C. Wainwright resumed coverage of Assembly Biosciences with a rating of Buy and set a new price target of $50.00

    8/18/25 8:55:27 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Assembly Biosciences with a new price target

    Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00

    3/25/25 8:26:24 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

    – Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (NASDAQ:GILD) and Assembly Biosciences, Inc. (NASDAQ:ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio R&D collaboration, reinforcing the companies' commitment to building a novel antiviral pipeline and driving long-term

    12/22/25 8:00:00 AM ET
    $ASMB
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

    – 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 – – Company to hold conference call today at 6 p.m. ET – SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting seri

    12/8/25 4:05:00 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

    – Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes – – Announced Phase 1a interim results for orally bioavailable HDV entry inhibitor candidate ABI-6250 supporting progression into Phase 2 evaluation – – Additional interim Phase 1b data readouts from HSV program anticipated to include monthly oral dosing for ABI-5366 and two cohorts of weekly oral dosing for ABI-1179, with data now expected by end of year – – Raised $175 million gross proceeds from equity financings – SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE)

    11/10/25 4:05:00 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gilead Sciences, Inc. bought 2,295,920 shares, increasing direct ownership by 104% to 4,505,391 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    10/3/25 4:30:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Houghton Michael bought $49,998 worth of shares (3,202 units at $15.61) (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    12/31/24 4:24:14 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $20,098,464 worth of shares (940,499 units at $21.37), increasing direct ownership by 74% to 2,209,471 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    12/23/24 8:26:39 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gilead Sciences, Inc. bought 2,295,920 shares, increasing direct ownership by 104% to 4,505,391 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    10/3/25 4:30:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PFO and PAO Bjorkquist Jeanette M was granted 300 shares, increasing direct ownership by 6% to 5,097 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/17/25 4:05:04 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Houghton Michael

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/9/25 4:05:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Assembly Biosciences Inc.

    SCHEDULE 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    2/9/26 8:46:31 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

    12/8/25 4:17:56 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Assembly Biosciences Inc.

    SCHEDULE 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    12/8/25 11:43:35 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Leadership Updates

    Live Leadership Updates

    View All

    Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

    -- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi

    11/8/23 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

    −ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv

    2/15/23 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

    Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

    1/17/23 7:00:00 AM ET
    $ASMB
    $PRDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $ASMB
    Financials

    Live finance-specific insights

    View All

    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

    – 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study – – 76% reduction in HSV-2 shedding rate, 81% reduction in high viral load shedding rate and 88% reduction in virologically confirmed genital lesion rate observed in proof-of-concept test of monthly oral dose of ABI-5366 – – Company to hold conference call today at 6 p.m. ET – SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting seri

    12/8/25 4:05:00 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Assembly Biosciences Inc.

    SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    11/14/24 3:22:29 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

    SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    6/24/24 4:28:09 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

    SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    6/20/24 8:35:37 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care